Related Experiment Videos
Clinical studies with dexfenfluramine: from past to future
1Service de Médecine et Nutrition, Hôtel-Dieu, Paris, France.
Obesity Research
|November 1, 1995
Summary
Fenfluramine (dF) aids weight loss and prevents regain in obesity management. This serotoninergic drug improves metabolic health and is a valuable addition to long-term obesity treatment strategies.
Area of Science:
- Pharmacology
- Endocrinology
- Obesity Research
Background:
- Obesity is a complex metabolic disorder requiring effective long-term management strategies.
- Pharmacotherapy is increasingly recognized as a component of comprehensive obesity treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of fenfluramine (dF) in managing human obesity.
- To assess dF's impact on weight loss, weight regain prevention, and metabolic risk factors.
Main Methods:
- Controlled clinical trials were conducted using fenfluramine (15 mg twice daily).
- Study outcomes included adherence to weight loss programs, percentage of patients achieving significant weight loss, weight regain, and changes in metabolic parameters.
Main Results:
- Fenfluramine (dF) doubled the number of patients achieving ≥10 kg weight loss compared to placebo with dietary counseling.
- dF use prevented weight regain over a 1-year period and predicted subsequent outcomes.
- Significant improvements in metabolic risk factors and blood pressure were observed, particularly in obesity-associated diseases.
Conclusions:
- Fenfluramine (dF) demonstrates efficacy in promoting sustained weight loss and improving metabolic health in obese patients.
- Long-term pharmacotherapy with dF may be a valuable strategy for managing obesity and preventing relapse.
- Integrated management plans including dF, diet, behavioral modification, and exercise are recommended for optimal patient outcomes.